University of Rochester Medical Center, Department of Urology, Rochester, NY.
University of Rochester Medical Center, Department of Urology, Rochester, NY.
Urol Oncol. 2020 Feb;38(2):38.e1-38.e8. doi: 10.1016/j.urolonc.2019.09.029. Epub 2019 Nov 18.
To assess clinicopathologic factors on MR/US fusion biopsy that might predict failure of theoretical selection criteria for prostatic hemigland ablation (HA).
A retrospectively maintained single institution multiparametric MRI database (n = 1667) was queried to identify 355 patients who underwent MR/US fusion biopsy, including both targeted biopsy and concurrent systematic biopsy from December 1, 2014 to June 1, 2018. Clinical, pathological, and imaging variables were assessed on fusion biopsy (Table 1) to determine who met theoretical selection criteria for HA, defined as unilateral intermediate-risk prostate cancer per NCCN criteria (Grade Group [GG] 2 or 3 with prostate-specific antigen <20) and no evidence of extraprostatic extension (EPE) on multiparametric MRI. Predictors of selection criteria failure were then assessed in patients who also underwent radical prostatectomy (RP). Failure of the theoretical HA selection criteria was defined as presence of GG ≧ 2 on the contralateral (untreated) side, or the presence of high-risk disease (any GG ≧ 4 or EPE) in the RP specimen.
Of the 355 patients who underwent fusion biopsy, 84 patients met the theoretical selection criteria for HA. Of those patients eligible, 54 underwent RP, 37 (68.5%) of which represented unsuccessful HA selection criteria. Patients no longer met HA selection criteria on the basis of upgrading alone in 6/54 (11.1%), EPE alone in 9/54 (16.7%), bilateral GG 2 or 3 in 16/54 (29.6%) or combined EPE and bilateral GG 2 or 3 in 6/54 (11.1%) cases. In the HA selection failures due to upgrading, three also had EPE, one of whom also had missed contralateral GG ≧ 2 disease. The only factor independently associated with HA failure was any presence of cribriform pattern (HR 7.01, P = 0.021). Perineural invasion on systematic biopsyalso appeared to improve the performance of our multivariable model (HR 5.33, P = 0.052), though it was not statistically significant when using a cutoff of <0.05. Accuracy for predicting successful HA was 0.32 and improved to 0.74 if PNI or cribriform were excluded and 0.84 if both were excluded.
In a retrospective analysis of RP patients who underwent preoperative MRI/US fusion biopsy, current selection criteria for prostatic HA based on NCCN intermediate-risk stratification failed to accurately identify appropriate candidates in 68.5% of patients. Cribriform pattern and PNI detected on biopsy reduced the failure of hemigland selection criteria to 43%. These criteria should be routinely reported on biopsy pathology and taken into consideration when selecting patients for HA in prospective clinical trials.
评估磁共振/超声融合活检的临床病理因素,这些因素可能预测前列腺半腺体消融(HA)理论选择标准的失败。
回顾性维护的单机构多参数 MRI 数据库(n=1667)被查询,以确定 355 名患者接受了磁共振/超声融合活检,包括 2014 年 12 月 1 日至 2018 年 6 月 1 日的靶向活检和同期系统活检。融合活检评估了临床、病理和影像学变量(表 1),以确定谁符合 HA 的理论选择标准,定义为单侧中危前列腺癌符合 NCCN 标准(GG 2 或 3,前列腺特异性抗原<20),多参数 MRI 无前列腺外延伸(EPE)证据。然后在接受根治性前列腺切除术(RP)的患者中评估预测选择标准失败的因素。HA 理论选择标准的失败定义为对侧(未治疗)侧 GG≧2,或 RP 标本中存在高危疾病(任何 GG≧4 或 EPE)。
在接受融合活检的 355 名患者中,84 名患者符合 HA 的理论选择标准。在符合条件的患者中,54 名患者接受了 RP,其中 37 名(68.5%)代表 HA 选择标准不成功。6/54(11.1%)例患者因升级 alone 不再符合 HA 选择标准,9/54(16.7%)例患者因 EPE alone 不再符合 HA 选择标准,16/54(29.6%)例患者因双侧 GG 2 或 3 不再符合 HA 选择标准,6/54(11.1%)例患者因 EPE 和双侧 GG 2 或 3 不再符合 HA 选择标准。在由于升级而导致 HA 选择失败的病例中,有 3 例患者还存在 EPE,其中 1 例患者还存在对侧 GG≧2 疾病。唯一与 HA 失败独立相关的因素是有无筛状模式(HR 7.01,P=0.021)。系统活检中的神经周围侵犯似乎也提高了我们多变量模型的性能(HR 5.33,P=0.052),尽管当使用<0.05 的截止值时,它并不具有统计学意义。预测 HA 成功的准确率为 0.32,如果排除 PNI 或筛状模式,则准确率提高至 0.74,如果同时排除两者,则准确率提高至 0.84。
在对接受术前 MRI/US 融合活检的 RP 患者进行的回顾性分析中,目前基于 NCCN 中危分层的前列腺 HA 选择标准在 68.5%的患者中未能准确识别合适的候选者。活检中检测到的筛状模式和 PNI 将半腺体选择标准的失败率降低至 43%。这些标准应在活检病理报告中常规报告,并在选择 HA 患者进行前瞻性临床试验时加以考虑。